GP210 Antibody, IgG, Serum
Use
Evaluating the risk of primary biliary cholangitis in anti-mitochondrial antibody (AMA)-negative patients by identification of gp210 antibodies. Estimating risk in AMA-positive patients with incomplete feature of disease. Primary biliary cholangitis (PBC) is a chronic and progressive autoimmune liver disease characterized by the destruction of small intrahepatic bile ducts and a variable clinical course.
Special Instructions
Not provided.
Limitations
The presence of primary biliary cholangitis (PBC)-specific autoantibodies, including anti-gp210, should not be relied upon exclusively to make a diagnosis of PBC or predict disease outcome. A negative result for anti-gp210 antibodies does not exclude a diagnosis of PBC. Results should be used in conjunction with clinical findings and other serological tests.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
gp210 antibody
Protein
LOINC Codes
- 96560-8 - Nuclear pore prot gp210 Ab Ser IA-aCnc
- 96560-8 - Nuclear pore prot gp210 Ab Ser IA-aCnc
Result Turnaround Time
2-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Heat-treated specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |